(Q55021320)

15 June 2018

title

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. (English)

1 reference

15 June 2018

1 reference

M Hanada

1

1 reference

15 June 2018

S Mizuno

2

1 reference

15 June 2018

A Fukushima

3

1 reference

15 June 2018

Y Saito

4

1 reference

15 June 2018

T Noguchi

5

1 reference

15 June 2018

T Yamaoka

6

1 reference

15 June 2018

publication date

1 November 1998

1 reference

15 June 2018

number of pages

10

1 reference

Japanese Journal of Cancer Research

inferred from page(s)

published in

1 reference

15 June 2018

volume

89

1 reference

15 June 2018

issue

11

1 reference

15 June 2018

page(s)

1229-1238

1 reference

15 June 2018

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

DNA Modification and Cancer

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Topoisomerase-targeting antitumor drugs

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

DNA topoisomerase poisons as antitumor drugs

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5921721

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives

16 June 2018

1 reference

12 December 2020

Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors

1 reference

12 December 2020

Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity

1 reference

12 December 2020

In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone

1 reference

12 December 2020

Inhibition of type II topoisomerase by fostriecin

1 reference

12 December 2020

1 reference

12 December 2020

DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II

1 reference

12 December 2020

[Phase I study of SM-5887, a new anthracycline derivative]

1 reference

12 December 2020

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

1 reference

12 December 2020

Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

1 reference

12 December 2020

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

12 December 2020

Interaction of doxorubicin with nuclei isolated from rat liver and kidney

1 reference

12 December 2020

Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship

1 reference

12 December 2020

Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme

1 reference

12 December 2020

10.1111/J.1349-7006.1998.TB00519.X

Identifiers

DOI

1 reference

15 June 2018

PMC publication ID

5921721

1 reference

15 June 2018

PubMed publication ID

9914793

1 reference

15 June 2018